NeoGenomics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

NeoGenomics wird ein jährliches Gewinn- und Umsatzwachstum von 32.1% bzw. 10.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 34.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 6.1% betragen.

Wichtige Informationen

32.1%

Wachstumsrate der Gewinne

34.3%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	21.1%
Wachstumsrate der Einnahmen	10.1%
Zukünftige Eigenkapitalrendite	6.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:NEO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	800	-37	4	N/A	8
12/31/2025	727	-54	-28	N/A	13
12/31/2024	662	-80	-58	N/A	13
9/30/2024	644	-78	-22	15	N/A
6/30/2024	628	-79	-30	0	N/A
3/31/2024	611	-84	-40	-15	N/A
12/31/2023	592	-88	-31	-2	N/A
9/30/2023	575	-96	-50	-23	N/A
6/30/2023	552	-115	-64	-34	N/A
3/31/2023	530	-126	-82	-50	N/A
12/31/2022	510	-144	-97	-66	N/A
9/30/2022	497	-163	-120	-82	N/A
6/30/2022	489	-147	-119	-74	N/A
3/31/2022	486	-36	-115	-58	N/A
12/31/2021	484	-8	-91	-27	N/A
9/30/2021	485	49	-65	-1	N/A
6/30/2021	489	72	-49	7	N/A
3/31/2021	454	-11	-30	11	N/A
12/31/2020	444	4	-28	1	N/A
9/30/2020	425	-5	-25	-1	N/A
6/30/2020	405	-5	-6	17	N/A
3/31/2020	419	3	-11	10	N/A
12/31/2019	409	8	3	23	N/A
9/30/2019	378	2	18	35	N/A
6/30/2019	343	2	13	25	N/A
3/31/2019	309	6	24	37	N/A
12/31/2018	277	6	30	45	N/A
9/30/2018	262	8	20	35	N/A
6/30/2018	252	-1	N/A	34	N/A
3/31/2018	246	-9	N/A	34	N/A
12/31/2017	240	-11	N/A	18	N/A
9/30/2017	239	-27	N/A	12	N/A
6/30/2017	241	-26	N/A	14	N/A
3/31/2017	242	-29	N/A	13	N/A
12/31/2016	232	-31	N/A	21	N/A
9/30/2016	211	-18	N/A	24	N/A
6/30/2016	175	-12	N/A	17	N/A
3/31/2016	136	-7	N/A	14	N/A
12/31/2015	100	-3	N/A	6	N/A
9/30/2015	98	0	N/A	5	N/A
6/30/2015	96	0	N/A	6	N/A
3/31/2015	92	0	N/A	8	N/A
12/31/2014	87	1	N/A	9	N/A
9/30/2014	80	1	N/A	8	N/A
6/30/2014	74	2	N/A	7	N/A
3/31/2014	69	2	N/A	5	N/A
12/31/2013	66	2	N/A	2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NEODie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: NEODie Einnahmen des Unternehmens (10.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NEODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (6.1%).

NeoGenomics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Consensus EPS estimates fall by 15%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

Price target increased by 7.2% to US$21.55

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock